Rocket Pharmaceuticals, Inc. (RCKT) Financials

RCKT Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 285.4 million 47.4 million
Dec. 31, 2025 330.4 million 53.2 million
Sept. 30, 2025 368.0 million 54.4 million
June 30, 2025 421.0 million 66.8 million

RCKT Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -45.5 million 8.5 million
Dec. 31, 2025 -34.9 million 6.1 million
Sept. 30, 2025 -50.4 million 9.8 million
June 30, 2025 -49.0 million 10.9 million

RCKT Net Income

No data available :(

RCKT Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 144.4 million - 21.8 million
Dec. 31, 2025 188.9 million - 22.0 million
Sept. 30, 2025 222.8 million - 22.1 million
June 30, 2025 271.5 million - 25.2 million

RCKT Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 112.1 million
Dec. 31, 2025 111.1 million
Sept. 30, 2025 111.6 million
June 30, 2025 111.0 million

RCKT Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 93000 31.5 million 17.1 million -
Dec. 31, 2025 80000 29.3 million 14.7 million -
Sept. 30, 2025 54000 34.1 million 18.4 million -
June 30, 2025 50000 42.7 million 25.0 million -

RCKT Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 2.1 million
Dec. 31, 2025 - -
Sept. 30, 2025 - -
June 30, 2025 - 2.5 million

RCKT

Price: $2.80

52 week price:
2.40
5.45

Earnings Per Share: -1.90 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 607900

Market Capitalization: 300.3 million

Links: